anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: OXYTOCIN
Trial phase: Phase 2
ATC code: H01BB02
SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 34
Group description: Participants will first receive a nasal spray containing the hormone oxytocin (24 IU, 3 puffs per nostril). After a one-week washout period, participants will come back to the clinic and receive a placebo nasal spray (containing all of the same ingredients as the oxytocin spray minus the active oxytocin ingredient).

Oxytocin: Oxytocin nasal sprays will be self-administered in the presence of a study nurse. The dose is 24 IU (3 puffs per nostril, 4 IU per puff) of Syntocinon nasal spray.
Eligibility criteria:
Inclusion Criteria:

Treatment-seeking adult males and females ≥ 18 years of age
Meets DSM-IV criteria for principal BDD (for BDD group) or principal OCD (for OCD group), as determined by Structured Clinical Interview for DSM-IV (SCID) diagnostic interview
For females only: must be taking low-dose oral contraceptive pills, as defined by monophasic pills containing <50 mcg ethinyl estradiol
For healthy volunteers only: does not meet current DSM-IV diagnosis of any Axis I disorder

Exclusion Criteria:

Participants in the BDD group will be excluded if they have a comorbid diagnosis of OCD and participants in the OCD group will be excluded if they have a comorbid diagnosis of BDD.
Current diagnosis of schizophrenia, psychotic disorder, bipolar disorder, substance abuse or substance dependence. All other Axis I comorbidities will be permitted to foster the accrual of a clinically relevant sample.
Significant nasal pathology (e.g., atrophic rhinitis, history of hypophysectomy, recurrent nosebleeds)
Smokers who smoke ≥ 15 cigarettes daily
Serious medical illnesses
Active homicidal or suicidal ideation
Concurrent use of psychotropic medications
Steroid or hormone use (except low-dose oral contraceptive pills for females, which is allowed)
For females only: positive urine pregnancy test and use of high dose estrogen/progestin pills (low dose estrogen/progestin oral contraceptives will be allowed due to stability of hormone levels during active phase)
For healthy volunteers only: any current DSM-IV Axis I disorder
Intervention: Gallium Ga-68 gozetotide
Trial phase: Phase 2 | Phase 3
ATC code: V09IX14
SMILES: O=C([O-])CCc1ccc(O)c(CN(CCN(CC(=O)[O-])Cc2cc(CCC(=O)NCCCCCC(=O)NCCCC[C@H](NC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)ccc2O)CC(=O)[O-])c1.[68Ga+3]
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 61
Group description: Patients receive 68Ga-PSMA-11. Participant will be injected IV with 3 to 7 mCi of 68Ga PSMA 11 Beginning 50 to 100 minutes later, a low dose CT will be obtained from vertex to mid thighs; followed by a static PET emission scan over the same.

68Ga-PSMA-11: Given IV
Computed Tomography: Undergo 68Ga-PSMA-11 PET/CT
Positron Emission Tomography: Undergo 68Ga-PSMA-11 PET/CT
Eligibility criteria:
Inclusion Criteria:

Histopathological proven prostate adenocarcinoma

Rising prostate-specific antigen (PSA) after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy)

Post radical prostatectomy (RP) - American Urology Association (AUA) recommendation

PSA greater than 0.2 ng/mL measured 6 to 13 weeks after RP
Confirmatory persistent PSA greater than 0.2 ng/mL (total of two PSA measurements greater than 0.2 ng/mL)

Post-radiation therapy -American Society for Radiation Oncology (ASTRO)-Phoenix consensus definition

A rise of PSA measurement of 2 or more ng/mL over the nadir
Karnofsky performance status of ≥ 50 (or Eastern Cooperative Oncology Group [ECOG] / World Health Organization [WHO] equivalent)
Able to provide written consent

Exclusion Criteria:

Investigational therapy for prostate cancer.
Unable to lie flat, still or tolerate a positron emission tomograpy (PET) scan.
Prior history of any other malignancy within the last 2 years, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized and superficial bladder cancer.
Intervention: Morphine
Trial phase: Phase 4
ATC code: A07DA52 | N02AA01 | N02AA51 | N02AG01
SMILES: [H][C@@]12C=C[C@H](O)[C@]3([H])Oc4c(O)ccc5c4[C@]13CCN(C)[C@]2([H])C5
Sex: All
Age groups: Older Adult
Healthy volunteers: No
Participants at risk: 30
Group description: intravenous Morphine given at 0.1 mg/kg as intravenous infusion (10 min) with a maximum dose of 10 mg.

Morphine: intravenous Morphine given at 0.1 mg/kg as intravenous infusion (10 min) with a maximum dose of 10 mg. The device is the Care Fusion Alaris PC.
Eligibility criteria:
Inclusion Criteria:

ED patients; 65 years of age and older; abdominal, flank, back, traumatic chest, neck or musculoskeletal pain; capacity to give verbal or written consent.

Exclusion Criteria:

ED patients <65 years old; altered mental status; presenting with headache, non-traumatic chest pain; allergy to morphine or ketamine; weight <40kg or >115kg, unstable vital signs (systolic blood pressure <90 or >180 mmHg; heart rate <5 or >150 beats per minute; and respirations <8 or >30 per minute), and past medical history of severe renal or hepatic insufficiency, alcohol or drug abuse or psychiatric illness; Patients with BMI>40; severe COPD
Intervention: Ketamine
Trial phase: Phase 4
ATC code: N01AX03 | N01AX14 | N06AX27
SMILES: CNC1(c2ccccc2Cl)CCCCC1=O
Sex: All
Age groups: Older Adult
Healthy volunteers: No
Participants at risk: 30
Group description: Ketamine administered in sub-dissociative doses 0.3 mg/kg as a intravenous infusion (10 min)

Ketamine: Ketamine administered in sub-dissociative doses 0.3 mg/kg as a intravenous infusion (10 min). The device is the Care Fusion Alaris PC.
Eligibility criteria:
Inclusion Criteria:

ED patients; 65 years of age and older; abdominal, flank, back, traumatic chest, neck or musculoskeletal pain; capacity to give verbal or written consent.

Exclusion Criteria:

ED patients <65 years old; altered mental status; presenting with headache, non-traumatic chest pain; allergy to morphine or ketamine; weight <40kg or >115kg, unstable vital signs (systolic blood pressure <90 or >180 mmHg; heart rate <5 or >150 beats per minute; and respirations <8 or >30 per minute), and past medical history of severe renal or hepatic insufficiency, alcohol or drug abuse or psychiatric illness; Patients with BMI>40; severe COPD
Intervention: Buspirone
Trial phase: Not Applicable
ATC code: N05BE01
SMILES: O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Buspirone 10 mg PO TID

Buspirone
Eligibility criteria:
Inclusion Criteria:

Diagnosis of IEM per Chicago Classification, v3.0 criteria - as noted above
Esophagogastroduodenoscopy (EGD) negative for mechanical obstruction
Esophageal biopsies negative for eosinophilic esophagitis

Exclusion Criteria:

Pregnant women
Prisoners
Currently on other serotonin modulating medications
Intervention: Tenapanor
Trial phase: Phase 3
ATC code: A06AX08
SMILES: CN1Cc2c(Cl)cc(Cl)cc2[C@H](c2cccc(S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)c3cccc([C@@H]4CN(C)Cc5c(Cl)cc(Cl)cc54)c3)c2)C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 74
Group description: Tenapanor, 3mg BID (6mg total)
Eligibility criteria:
Inclusion Criteria:

18 to 80 years old
Females must be non-pregnant, non-lactating, and either be post-menopausal for at least 12 months, have documentation of irreversible surgical sterilization, or confirm the use of one of the acceptable contraceptive methods.
Males must agree to avoid fathering a child and agree to use an appropriate method of contraception
Chronic maintenance hemodialysis 3x/week for at least 3 months
Kt/V ≥ 1.3 at most recent measurement prior to screening
Prescribed and taking at least 3 doses of phosphate binder per day
Serum phosphate levels should be between 4.0 and 7.0 mg/dL (inclusive) at screening
For randomization in the study, after 1 week wash-out of phosphate binders, subjects must have serum phosphate level of at least 9 mg/dL but below 10 mg/dL and have had an increase of at least 1.5 mg/dL versus pre-wash out value
For randomization in the study, after 2 or 3 weeks wash-out of phosphate binders, subjects must have serum phosphate level of at least 6 mg/dL but below 10 mg/dL and have had an increase of at least 1.5 mg/dL versus pre-wash out value

Exclusion Criteria:

Severe hyperphosphatemia defined as >10 mg/dL on Phosphate-binders at any time point during clinical routine monitoring for the 3 preceding months before screening
Serum parathyroid hormone >1200 pg/mL
Persistent metabolic acidosis defined as serum carbon dioxide <18 mmol/L from two consecutive measurements during screening and washout periods
Clinical signs of hypovolemia at randomization
History of inflammatory bowel disease (IBD) or diarrhea predominant irritable bowel syndrome (IBS-D)
Scheduled for living donor kidney transplant, change to peritoneal dialysis, home HD or plans to relocate to another center during the study period
Diarrhea or loose stools during the week before randomization defined as BSFS ≥ 6 and frequency ≥ 3 for 2 or more days
Any evidence of or treatment of malignancy within one year, excluding non-melanomatous malignancies of the skin
Positive serology with evidence of significant hepatic impairment or WBC elevation according to the Investigator
Life expectancy < 6 months
Intervention: Tenapanor
Trial phase: Phase 3
ATC code: A06AX08
SMILES: CN1Cc2c(Cl)cc(Cl)cc2[C@H](c2cccc(S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)c3cccc([C@@H]4CN(C)Cc5c(Cl)cc(Cl)cc54)c3)c2)C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 73
Group description: Tenapanor, 10mg BID (20mg total)
Eligibility criteria:
Inclusion Criteria:

18 to 80 years old
Females must be non-pregnant, non-lactating, and either be post-menopausal for at least 12 months, have documentation of irreversible surgical sterilization, or confirm the use of one of the acceptable contraceptive methods.
Males must agree to avoid fathering a child and agree to use an appropriate method of contraception
Chronic maintenance hemodialysis 3x/week for at least 3 months
Kt/V ≥ 1.3 at most recent measurement prior to screening
Prescribed and taking at least 3 doses of phosphate binder per day
Serum phosphate levels should be between 4.0 and 7.0 mg/dL (inclusive) at screening
For randomization in the study, after 1 week wash-out of phosphate binders, subjects must have serum phosphate level of at least 9 mg/dL but below 10 mg/dL and have had an increase of at least 1.5 mg/dL versus pre-wash out value
For randomization in the study, after 2 or 3 weeks wash-out of phosphate binders, subjects must have serum phosphate level of at least 6 mg/dL but below 10 mg/dL and have had an increase of at least 1.5 mg/dL versus pre-wash out value

Exclusion Criteria:

Severe hyperphosphatemia defined as >10 mg/dL on Phosphate-binders at any time point during clinical routine monitoring for the 3 preceding months before screening
Serum parathyroid hormone >1200 pg/mL
Persistent metabolic acidosis defined as serum carbon dioxide <18 mmol/L from two consecutive measurements during screening and washout periods
Clinical signs of hypovolemia at randomization
History of inflammatory bowel disease (IBD) or diarrhea predominant irritable bowel syndrome (IBS-D)
Scheduled for living donor kidney transplant, change to peritoneal dialysis, home HD or plans to relocate to another center during the study period
Diarrhea or loose stools during the week before randomization defined as BSFS ≥ 6 and frequency ≥ 3 for 2 or more days
Any evidence of or treatment of malignancy within one year, excluding non-melanomatous malignancies of the skin
Positive serology with evidence of significant hepatic impairment or WBC elevation according to the Investigator
Life expectancy < 6 months
Intervention: Tenapanor
Trial phase: Phase 3
ATC code: A06AX08
SMILES: CN1Cc2c(Cl)cc(Cl)cc2[C@H](c2cccc(S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)c3cccc([C@@H]4CN(C)Cc5c(Cl)cc(Cl)cc54)c3)c2)C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 72
Group description: Tenapanor, patients start at 30mg BID and can down titrate weekly to 20, 15, 10, and 3mg BID, sequentially based on a GI tolerability question
Eligibility criteria:
Inclusion Criteria:

18 to 80 years old
Females must be non-pregnant, non-lactating, and either be post-menopausal for at least 12 months, have documentation of irreversible surgical sterilization, or confirm the use of one of the acceptable contraceptive methods.
Males must agree to avoid fathering a child and agree to use an appropriate method of contraception
Chronic maintenance hemodialysis 3x/week for at least 3 months
Kt/V ≥ 1.3 at most recent measurement prior to screening
Prescribed and taking at least 3 doses of phosphate binder per day
Serum phosphate levels should be between 4.0 and 7.0 mg/dL (inclusive) at screening
For randomization in the study, after 1 week wash-out of phosphate binders, subjects must have serum phosphate level of at least 9 mg/dL but below 10 mg/dL and have had an increase of at least 1.5 mg/dL versus pre-wash out value
For randomization in the study, after 2 or 3 weeks wash-out of phosphate binders, subjects must have serum phosphate level of at least 6 mg/dL but below 10 mg/dL and have had an increase of at least 1.5 mg/dL versus pre-wash out value

Exclusion Criteria:

Severe hyperphosphatemia defined as >10 mg/dL on Phosphate-binders at any time point during clinical routine monitoring for the 3 preceding months before screening
Serum parathyroid hormone >1200 pg/mL
Persistent metabolic acidosis defined as serum carbon dioxide <18 mmol/L from two consecutive measurements during screening and washout periods
Clinical signs of hypovolemia at randomization
History of inflammatory bowel disease (IBD) or diarrhea predominant irritable bowel syndrome (IBS-D)
Scheduled for living donor kidney transplant, change to peritoneal dialysis, home HD or plans to relocate to another center during the study period
Diarrhea or loose stools during the week before randomization defined as BSFS ≥ 6 and frequency ≥ 3 for 2 or more days
Any evidence of or treatment of malignancy within one year, excluding non-melanomatous malignancies of the skin
Positive serology with evidence of significant hepatic impairment or WBC elevation according to the Investigator
Life expectancy < 6 months
Intervention: Gallium Ga-68 gozetotide
Trial phase: Phase 2 | Phase 3
ATC code: V09IX14
SMILES: O=C([O-])CCc1ccc(O)c(CN(CCN(CC(=O)[O-])Cc2cc(CCC(=O)NCCCCCC(=O)NCCCC[C@H](NC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)ccc2O)CC(=O)[O-])c1.[68Ga+3]
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 74
Group description: Patients receive 68Ga-PSMA-11 IV. Patients then undergo PET/MRI after 45 minutes of administration of radiopharmaceutical injection.

68Ga-PSMA-11: Undergo 68Ga-PSMA-11 PET/MRI Magnetic resonance imaging (MRI): Undergo 68Ga-PSMA-11 PET/MRI Positron Emission Tomography (PET): Undergo 68Ga-PSMA-11 PET/MRI
Eligibility criteria:
INCLUSION CRITERIA

Biopsy-proven prostate adenocarcinoma
Planned prostatectomy with lymph node dissection
Intermediate- to high-risk disease (as determined by elevated prostate-specific antigen (PSA) [PSA > 10], T stage [T2b or greater], Gleason score [Gleason score > 6] or other risk factors)
Karnofsky performance status of ≥ 50 [or Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) equivalent]
Diagnostic CT or MRI performed within 90 days of the research PET
Able to provide written consent

ExCLUSION CRITERIA

Patients not capable of getting PET study due to weight, claustrophobia, or inability to lay still for the duration of the exam
Neoadjuvant chemotherapy or radiation therapy prior to prostatectomy, including focal ablation techniques (HiFu)
Androgen deprivation therapy or other neoadjuvant treatments prior to PET imaging and surgery
Metallic implants (contraindicated for MRI)
Intervention: Testosterone
Trial phase: Early Phase 1
ATC code: G03BA03 | G03EA02
SMILES: [H][C@@]12CCC3=CC(=O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H](O)CC[C@@]21[H]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 3
Group description: Testosterone Enanthate injections (25mg/injection females; 100mg/injection males) to be received on weeks 0, 1, 4, 5, 8 and 9.

Testosterone: Intermittent intramuscular injections of 100 mg Testosterone Enanthate (males) or 25 mg Testosterone Enanthate (females).
Eligibility criteria:
Inclusion Criteria:

Male or Female
Ages: 60 years or older
Starting rehabilitative care

Exclusion Criteria:

Inability to perform the functional tests specific to the study protocol
Diagnosed with carcinomas of the breast or with known or suspected carcinomas of the prostate.
Uncontrolled endocrine or metabolic disease (e.g. liver disease, renal disease, diabetes).
Uncontrolled hypertension. Systolic blood pressure =/> 160mm Hg or a diastolic blood pressure =/> 100mm Hg on three consecutive measurements taken at one-week intervals. Testosterone, other anabolic steroids and glucocorticoids can cause fluid retention that could worsen uncontrolled hypertension. Subjects will be included if they are on two or less blood pressure medications and have a blood pressure below these criteria.
History of significant liver disorders or a 3-fold elevation of liver function tests (Alk phos, ALT, AST). Testosterone can have hepatotoxic effects in some subjects and should be used with careful monitoring of LFTs (liver function), though injections of testosterone at a 100 mg dose is not typically sufficient to negatively affect LFTs.
History of angina that occurs with exertion or at rest or a myocardial infarction within the last 12 months.
LDL cholesterol greater than 200 mg/dL as testosterone administration may elevate LDL cholesterol levels further, though this is not anticipated with testosterone injections of 100 mg/wk.
Hematocrit greater than 51%.
Established chronic obstructive pulmonary disease, or untreated sleep apnea.
Implanted artificial pacemaker/defibrillator. BIA uses small currents and is not recommended for participants with a pacemaker.
Diagnosed systemic fungal infections.
Positive screening for HIV or active hepatitis*.
Use of or history of recent anabolic steroid use (within 3 months).
Alcohol or drug abuse.
Any other condition or event considered exclusionary by the PI and covering faculty physician.

Vulnerable populations including: individuals unable to consent on their own behalf, prisoners and pregnant women.

Subjects excluded due to positive screening results, including HIV, HBV or HCV, will be immediately scheduled for counseling and follow-up testing as needed, and will be advised to consult their primary physician.
Intervention: Nalmefene Hydrochloride
Trial phase: Phase 1
SMILES: C=C1CCC2(O)C3Cc4ccc(O)c5c4C2(CCN3CC2CC2)C1O5.Cl
Sex: Male
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 7
Group description: nalmefene 10 mg tablet

nalmefene hydrochloride 10 mg
Eligibility criteria:
Inclusion Criteria:

The subject is a Japanese male.
The subject is able to read and understand the informed consent form (ICF).
The subject has a body mass index (BMI) ≥ 19 kg/m2 and ≤ 25 kg/m2 at the screening visit.
The subject has a resting pulse and heart rate (as read on the ECG) ≥ 45 bpm and ≤ 100 bpm at the screening visit.

Exclusion Criteria:

The subject has taken any prescription drugs, over-the counter medications, vitamin supplements, or supplements containing St. John's Wort (Hypericum perforatum) within 2 weeks prior to Day 1.
The subject has a significant history of alcohol abuse, defined as an alcohol intake greater than 21 units per week. (A unit of alcohol is defined as 250 mL of lager/beer, 100 mL of wine, or 25 mL of spirits.)
The subject has taken any investigational products within 4 months prior to Day 1.
Intervention: Bupivacaine
Trial phase: Phase 2
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1
Group description: In patients with femur or hip fractures, a fascia iliaca compartment block using liposomal bupivacaine will be administered

Liposomal Bupivacaine: A fascia iliaca compartment block using liposomal bupivacaine will require less total opioid administration compared to a fascia iliaca block using 0.2% ropivacaine
Eligibility criteria:
Inclusion Criteria:

age ≥18 years ≤ 70 years
Patient's s/p trauma, with confirmed femur and/or hip fractures with a planned admission to the hospital
Patient is ambulatory without assistance (e.g. walker, cane, caretaker) prior to incident.

Exclusion Criteria:

>10 hours since presentation to the emergency department
History of seizure disorder, recent seizure or a document intra-cranial hemorrhage.
Central or peripheral neurologic deficit on presentation
Concern or compartment syndrome
Associated additional long bone fractures
End stage liver failure
Renal failure requiring dialysis
Pregnancy or breast feeding
Prisoners
Coagulopathy with INR >1.5
Use of direct thrombin inhibitors (bivalirudin, argatroban, desirudin, dabigatran etexilate), or direct factor Xa inhibitors (rivaroxaban, apixaban, edoxaban)
Suspected prolonged intubation within first 12 hours secondary to respiratory failure other than peri-procedurally
Adults unable to consent
Pediatric patients <18 years old
Patients exhibiting signs of shock upon admission, HR >120 or SBP <100 mmHg.
History of allergic reaction to local anesthetics
Administration of any other local anesthetic in the 2 hours prior to the study enrollment.
Distal femur fractures
Intervention: Ropivacaine hydrochloride
Trial phase: Phase 2
SMILES: CCCN1CCCCC1C(=O)Nc1c(C)cccc1C.Cl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 2
Group description: In patients with femur or hip fractures, a fascia iliaca block using using 0.2% ropivacaine will be administered

Ropivacaine HCL: Ropivacaine HCL is a member of the amino amide class of local anesthetics. Naropin injection is a sterile, isotonic solution that contains the enantiomerically pure drug substance, sodium chloride for isotonicity and water for injection. It is administered parenterally.
Eligibility criteria:
Inclusion Criteria:

age ≥18 years ≤ 70 years
Patient's s/p trauma, with confirmed femur and/or hip fractures with a planned admission to the hospital
Patient is ambulatory without assistance (e.g. walker, cane, caretaker) prior to incident.

Exclusion Criteria:

>10 hours since presentation to the emergency department
History of seizure disorder, recent seizure or a document intra-cranial hemorrhage.
Central or peripheral neurologic deficit on presentation
Concern or compartment syndrome
Associated additional long bone fractures
End stage liver failure
Renal failure requiring dialysis
Pregnancy or breast feeding
Prisoners
Coagulopathy with INR >1.5
Use of direct thrombin inhibitors (bivalirudin, argatroban, desirudin, dabigatran etexilate), or direct factor Xa inhibitors (rivaroxaban, apixaban, edoxaban)
Suspected prolonged intubation within first 12 hours secondary to respiratory failure other than peri-procedurally
Adults unable to consent
Pediatric patients <18 years old
Patients exhibiting signs of shock upon admission, HR >120 or SBP <100 mmHg.
History of allergic reaction to local anesthetics
Administration of any other local anesthetic in the 2 hours prior to the study enrollment.
Distal femur fractures